新辅助化疗没有改善cT2N0M0胃腺癌患者的生存率:一个多中心倾向得分分析
Francesco Abboretti1,2, Céline Lambert3, Markus Schäfer1,2
1Department of Visceral Surgery, Lausanne University Hospital, CHUV, Lausanne, Switzerland.
Annals of surgical oncology
|May 18, 2024
概括
新辅助化疗并没有改善患有cT2N0M0期胃腺癌的患者的生存结果. 前置手术显示,与经过手术后的新辅助化疗相比,总体生存率和无病生存率相似.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 目前的指导方针建议在cT2N0M0胃腺癌阶段进行新辅助化疗,然后进行手术.
- 然而,由于患者的因素和当地偏好,在临床实践中经常选择前置手术.
研究的目的:
- 评估新辅助化疗对cT2N0M0胃腺癌患者的整体生存期 (OS) 和无病生存期 (DFS) 的影响.
主要方法:
- 从2007年到2017年,对32个中心的202名患者进行了回顾性分析.
- 患者被分为前期手术 (S) 和新辅助化疗,其次是手术 (CS) 组.
- 使用治疗权重的逆概率 (IPTW) 来调整基线差异.
主要成果:
- 在IPTW后,CS和S组之间的复发率没有显著差异 (27.2%对19.6%,p=0.32).
- 五年OS (78.9%对68.3%,p=0.42) 和5年DFS (70.4%对68.5%,p=0.96) 在两组之间是相似的.
- 在IPTW后的多变量分析表明,新辅助化疗与改善的OS或DFS无关.
结论:
- 与前期手术相比,经过手术后的新辅助化疗对cT2N0M0胃腺癌患者没有提供生存或复发益处.
- 这些发现表明,前置手术可能是这个患者群体的可行替代方案.
更多相关视频
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
674
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159